Daniel E . Hilleman, PharmD

Department

Pharmacy Practice

Position

Professor

Books

• Drug-induced Diseases: Prevention, Detection, and Management
  Malesker MA, Hilleman DE. Chapter 45: “Drug Induced SIADH and DI”; Drug-induced Diseases: Prevention, Detection and Management, 3rd Edition, Editors Tisdale J, Miller DA. ASHP Press; E5310; ISBN: 978-1-58528-531-0 97, 2018.
  3rd ed 2018
• Springer Science+Business Media LLC
  Hilleman DE, Campbell J. Medication adherence in heart failure: In: The Kidney in Heart Failure; 2nd Edition. Edited by George Bakris, New York, New York: Springer Science, 2012. 2012

Articles

• Current Problems in Cardiology (IF 4.19)
  Gill, G.S., Gill, G.S., Latif, A., Hilleman, D., Lavie, C., & Alla, V.M. (2021). Challenges in Implementing Evidence Based Cross-Disciplinary Therapies: Are Cardiovascular Specialists Ready to Claim SGLT-2 Inhibitors and GLP-1 Analogs? Current problems in cardiology, 100878 . 2021
• Future Cardiology Journal
  Backes, J., Backes, J., & Hilleman, D. (2021). New and emerging lipid-lowering therapy. Future cardiology. 2021
• Journal of the American Pharmacists Association
  Awadh, A. A., Awadh, A.A., Hilleman, D., Knezevich, E.L., Malesker, M., & Gallagher, J.C. (2021). Vitamin D supplements: The pharmacists' perspective. Journal of the American Pharmacists Association : JAPhA. 2021
• U.S. Pharmacist
  JM Backes, Backes JM, Hilleman DE. Lipid-lowering therapies: a review of current and future options. US Pharmacist 2021; February: www.uspharmacist.com. 2021
• Pain Medicine
  Hilleman, D., , Hilleman, D., Malesker, M., Aurit, S., & Morrow, L. (2020). Evidence for the Efficacy of an Opioid-Sparing Effect of Intravenous Acetaminophen in the Surgery Patient: A Systematic Review. Pain medicine. 2020
• Advances in Therapy
  Hilleman, D., , Hilleman, D., Wiggins, B., & Bottorff, M. (2020). A Response to: Letter to the Editor Regarding “Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: a Narrative Review”. Advances in Therapy, 37, 4046 - 4048.
  37, p. 4046-4048 2020
• Advances in Therapy
  Hilleman, D., , Hilleman, D., Wiggins, B., & Bottorff, M. (2020). Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review. Advances in Therapy, 37, 656 - 670.
  37, p. 656-670 2020
• Critical Care Medicine
  Malesker, M., Malesker, M., Hilleman, D., Aurit, S., & Morrow, L. (2020). 916: A SYSTEMATIC REVIEW OF OPIOID-SPARING EFFECT OF INTRAVENOUS ACETAMINOPHEN IN ADULT SURGERY PATIENTS. Critical Care Medicine, 48, 437.
  48, p. 437 2020
• P & T : a peer-reviewed journal for formulary management
  Wells, A., Wells, A., Woods, A., Hilleman, D., & Malesker, M. (2019). Alpha-1 Antitrypsin Replacement in Patients With COPD. P & T : a peer-reviewed journal for formulary management, 44 7, 412-415 .
  44 7, p. 412-415 2019
• American Journal of Respiratory and Critical Care Medicine
  Malesker, M., Malesker, M., Hilleman, D., & Morrow, L. (2019). Systematic Review of Intravenous Acetaminophen After Cardiac Surgery. 2019
• Journal of Pharmacy Practice
  Hilleman, D., , Hilleman, D., Teply, R.M., & Packard, K. (2019). Knowledge, Perceptions, and Patterns of Fish Oil Use in Cardiac Patients. Journal of Pharmacy Practice, 33, 580 - 585.
  33, p. 580-585 2019
• Pharmacy and Therapeutics
  DE Hilleman, Hilleman DE, Malesker MA, Hannig D. Direct-acting oral anticoagulant use in special populations. P&T 2019; 44: 619-628
  44, p. 619-628 2019
• Journal of Drug Assessment
  Schardt, G., Schardt, G., Wolfe, M., Nolan, K., Murray, J., & Hilleman, D. (2018). ESC/EAS clinical guidance recommendations: impact on patient eligibility for PCSK9 inhibitor therapy. Journal of Drug Assessment, 7, 8 - 8.
  7, p. 8 2018
• Journal of Drug Assessment
  Wolfe, M., Wolfe, M., Hilleman, D., Nolan, K., & Schardt, G. (2018). Impact of a dedicated medication access coordinator on PCSK9 inhibitor approval rates. Journal of Drug Assessment, 7, 9 - 9.
  7, p. 9 2018
• Journal of Cardiac Failure
  Packard, K., Packard, K., & Hilleman, D. (2018). Initiation of Sacubitril/Valsartan Early after Heart Failure Decompensation. Journal of Cardiac Failure, 24.
  24 2018
• American Journal of Health-System Pharmacy
  MA Malesker, Malesker MA, Aurit S, Hilleman DE. Gastrointestinal tract recovery in patients undergoing selected surgical procedures. Am J Health-Sys Pharm 2018; 75 (Suppl 4): S87-S88.
  75, p. S87-S88 2018
• Journal of Clinical Lipidology
  Hilleman, D., , Hilleman, D., Teply, R.M., & Packard, K. (2018). Knowledge, Perceptions, and Patterns of Fish Oil “Use in Cardiac Patients' †. Journal of Clinical Lipidology, 12, 552-553.
  12, p. 552-553 2018
• Specialty Pharmacy Times
  Hilleman DE, Malesker MA. A pharmacist’s review of hereditary angioedema management: diagnosis, treatment, and cost. Specialty Pharmacy Times 2018; 7: 40-52.
  7, p. 40-52 2018
• treatment of depression in patients with concomitant cardiac disease
  Teply RM, Packard KA, White ND, Hilleman DE, DiNicolantonio JJ. Treatment of depression in patients with concomitant cardiac disease. Prog Cardiovasc Dis 2016; 58: 514-528. 2016
• Clinical Lipidology
  Backes J, Anzalone D, Hilleman D, Catini J. The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia. Lipid in Health and Disease 2016; 15: 118-128. 2016
• American Journal of Managed Care
  Hilleman DE, Smer A. Prescription omega-3 fatty acid products and dietary supplements are not interchangeable. Managed Care 2016; 25: 46-52. 2016
• LipidSpin
  Mason RP, Hilleman DE. Omega-3 fatty acid fish oil dietary supplements for disease management: are they appropriate for patients? Lipid Spin 2016; 14: 29-31.
  14, p. 29-31 2016
• Journal of Surgery
  Malesker MA, Bruckner AL, Loggie B, Hilleman DE. IV acetaminophen: assessment of medication utilization evaluation data in peri-operative pain management. J Surgery 2015; 10:6-10.
  10, p. 6-10 2015
• Nebraska Mortar and Pestle
  Hilleman DE, Burns TL. Update on recently approved pharmacotherapy in the management of obesity. Nebraska Mortar & Pestle 2015; Mar/Apr: 19-27., p. 19-27 2015
• Annals of Pharmacotherapy
  Au, T. H., Bruckner, A., Mohiuddin, S. M., Hilleman, D. E. The prevention of contrast-induced nephropathy
  48, p. 1332-1342 2014
• Cardiovascular Therapeutics
  Ling, Hua, Burns, Tammy L., Hilleman, Daniel E. An Update on the Clinical Development of Proprotein Convertase Subtilisin Kexin 9 Inhibitors, Novel Therapeutic Agents for Lowering Low-Density Lipoprotein Cholesterol
  32, p. 82-88 2014
• Cardiology Research
  Campbell, JA, Teply, R., Mooss, AN, Hilleman, DE Impact of grapefruit juice on the antiplatelet activity of loading and maintenance doses of clopidogrel in healthy volunteers.
  5, p. 32-38 2014
• Clinical Medicine Insights: Cardiology
  Hilleman, DE, Malesker, MA Potenial benefits of icosapent ethyl on the lipid profile: case studies.
  8, p. 13-15 2014
• Journal of Managed Care Pharmacy : JMCP
  Hilleman, D. E. Adherence and health care costs with single-pill fixed-dose combinations in hypertension management
  20, p. 93-100 2014
• Pharmacotherapy
  Au TH, Bruckner A, Mohiuddin SM, Hilleman DE. The prevention of contrast-induced nephropathy. Annals of Pharmacotherapy 2014; 48: 971-976.
  48, p. 971-976 2014
• Cardiology Research
  Gorthi J, Hunter CB, Mooss AN, All VM, Hilleman DE. Reducing heart failure readmissions: a systematic review of disease management programs. Cardiol Res 2014; 5: 126-138.
  5, p. 126-138 2014
• Pharmacy Education
  Packard K, Gibu M, Teply R, Hilleman D, Qi Y. Pharmacy student intervention acceptance on a cardiology rotation. Pharmacy Education 2014; 14: 64-69.
  14, p. 64-69 2014
• Pharmacotherapy
  Ling, Hua, Lenz, Thomas L., Burns, Tammy L., Hilleman, Daniel E. Reducing the Risk of Obesity: Defining the Role of Weight Loss Drugs
  33, p. 1308-1321 2013
• American Journal of Cardiovascular Drugs
  Ling, Hua, Packard, Kathleen A., Burns, Tammy L., Hilleman, Daniel E. Impact of Ranolazine on Clinical Outcomes and Healthcare Resource Utilization in Patients with Refractory Angina Pectoris
  13, p. 407-412 2013
• Clinical Lipidology
  Hilleman, Daniel E. Optimal use of lipid-altering therapy: guidelines versus evidence
  8, p. 269-272 2013
• World Medical & Health Policy
  Burns, Tammy L., Ruckman, Jilyan A., Ling, Hua, Washington-Krauth, Shavonne M., Hilleman, Daniel E., Mohiuddin, Syed M. Current State of United States Tobacco Control Initiatives
  5, p. 245-259 2013
• Cardiology Research
  Ling H, Luoma JT, Hilleman DE. A review of currently available fenofibrate and fenofibric acid formulations. Cardiol Res 2013: 4: 47-55.
  4, p. 47-55 2013
• Pharmacy and Therapeutics
  Bradberry JC, Hilleman DE. Omega-3 fatty acids: overview of current therapies. P & T 2013: 38: 681-691.
  38, p. 681-691 2013
• Journal of Critical Care
  Malesker, Mark A., Hilleman, Daniel E. Intravenous labetalol compared with intravenous nicardipine in the management of hypertension in critically Ill patients
  27, p. 528.e7-528.e14 2012
• Cardiology Research
  Hawkins EB, Ling H, Burns TL, Mooss AN, Hilleman DE. Aliskiren in patients failing to achieve blood pressure targets with angiotensin converting enzyme inhibitors or angiotensin receptor blockers. Cardiology Res 2012; 3:147-153.
  3, p. 147-153 2012
• American Journal of Pharmacy Benefits
  Hilleman DE. New oral anticoagulants for stroke prevention in atrial fibrillation. Am J Pharmacy Benefits 2012; 4: 356-362.
  4, p. 356-362 2012
• Postgraduate Medicine
  Ling H, Burns TL, Hilleman DE. Novel strategies for managing dyslipidemia: treatment beyond statins. Postgraduate Medicine 2012; 124: 43-54.
  124, p. 43-54 2012
• American Journal of Emergency Medicine
  Peacock WF 4th, Hilleman DE, Levy PD, Rhoney DH, Varon J. A systematic review of nicardipine vs labetalol for the management of hypertensive crises. Am J Emergency Med 2012; 30: 981-983.
  30, p. 981-983 2012
• American Journal of Therapeutics
  Deshmukh A, Hilleman D, Del Core M, Nair CK. Antithrombotic regimens in patients with indication for long-term anticoagulation undergoing coronary interventions – systematic analysis, review of literature, and implications on management. Am J Ther 2011; 18: 203-210.
  18, p. 203-210 2011
• International journal of chronic obstructive pulmonary disease
  Dewan NA, Rice KL, Caldwell M, Hilleman DE. Economic evaluation of a disease management program for chronic obstructive pulmonary disease. J Chronic Pulm Dis 2011; 8: 153-159.
  8, p. 153-159 2011
• Coronary Artery Diesease
  Go J, Narmi A, Sype J, Mooss AN, Hilleman DE. Impact of renal dysfunction on the prognostic value of the TIMI risk score in patients with non-ST elevation acute coronary syndrome. Coronary Artery Disease 2011; 22: 411-415.
  22, p. 411-415 2011
• Pharmacotherapy
  Hilleman DE, Campbell J. Efficacy, safety, and cost of thrombolytic agents for the management of dysfunctional hemodialysis catheters: a systematic review. Pharmacotherapy 2011; 31: 1031-1040.
  31, p. 1031-1040 2011
• Seminars in thrombosis and hemostasis
  Campbell, J., Hilleman, D. Recombinant Peptides in Thrombolysis
  36, p. 529-536 2010
• Pharmacotherapy
  Packard, K. A., Hilleman, D. E., Davis, Estella M. Pharmacologic prophylaxis of postoperative atrial fibrillation in patients undergoing cardiac surgery: beyond beta-blockers
  30, p. 749 2010
• Managed Care
  Malesker, M. A., Hilleman, D. E. Comparison of amlodipine/valsartan fixed-dose combination therapy and conventional therapy
  19, p. 36-42 2010
• Formulary
  Campbell, Jennifer, Hilleman, Daniel Reducing cardiovascular risk in patients with type 2 diabetes: management of dyslipidemia
  45, p. 124-134 2010
• Expert Opinion on Pharmacotherapy
  Schima, S. M., Maciejewski, S. R., Hilleman, D. E., Williams, M. A., Mohiuddin, S. M. Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid
  11, p. 731-738 2010
• Journal of Asthma and Allergy
  Teply, Robyn M., Campbell, J., Hilleman, D. Current trends in the treatment of asthma: focus on simultaneous administration of salmeterol/fluticasone
  3, p. 1-8 2010
• Chest
  Hilleman, D. E., Dewan, N., Malesker, M., Friedman, M. Pharmacoeconomic evaluation of COPD
  136, p. e30 2009
• International journal of chronic obstructive pulmonary disease
  Hilleman, D. E., Malesker, M. A., Morrow, L. E., Schuller, D. A systematic review of the cardiovascular risk of inhaled anticholinergics in patients with COPD
  4, p. 253-263 2009
• Pharmacotherapy
  Maciejewski, S., Hilleman, D. Effettiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia
  28, p. 570-575 2008
• Journal of Vascular and Interventional Radiology
  Hilleman, D. E., Razavi, M. K. Clinical and economic evaluation of the Trellis-8 infusion catheter for deep vein thrombosis
  19, p. 377-383 2008
• Consultant Pharmacist
  Coover, K., Ryan-Haddad, Ann, Faulkner, M., Hilleman, Daniel E. Prevalence, treatment and control of hypertension in residents of skilled nursing facilities
  23, p. 317-323 2008
• Pharmacotherapy
  Hilleman, Daniel E., Tsikouris, James P., Seales, Allen, Marmur, Jonathan D. Fibrinolytic Agents for the Management of ST-Segment Elevation Myocardial Infarction
  27, p. 1558-1570 2007
• American Journal of Critical Care
  Malesker, M. A., Foral, P. A., McPhillips, A. C., Christensen, K. J., Chang, J. A., Hilleman, D. E. An efficiency evaluation of protocols for tight glycemic control in intensive care units
  16, p. 589-598 2007
• Pharmacotherapy
  Burns, T., Madejewski, S. R., Hamilton, W. R., Zheng, M., Mooss, A. N., Hilleman, D. E. Effect of omega-3 fatty acid supplementation on the arachidonic acid: Eicosapentaenoic acid ratio
  27, p. 633-638 2007
• Pharmacotherapy
  Buckley, M. S., Nolan, P. E., Slack, M. K., Tisdale, J. E., Hilleman, D. E., Copeland, J. G. Amiodarone prophylaxis for atrial fibrillation after cardiac surgery: Meta-analysis of dose response and timing of initiation
  27, p. 360-368 2007
• Biodrugs
  Simpson, D., Siddiqui, M. A. A., Scott, L. J., Hilleman, D. E. Spotlight on reteplase in thrombotic occlusive disorders
  21, p. 65-68 2007
• Critical Care Medicine
  Van den Berghe, G., Wouters, P. J., Kesteloot, K., Hilleman, D. E. Analysis of healthcare resource utilization with intensive insulin therapy in critically ill patients
  34, p. 612-616 2006
• Pharmacotherapy
  Maciejewski, S., Mohiuddin, S. M., Packard, K. A., Mooss, A. N., Reyes, A. P., Aryana, A., Hilleman, D. E. Randomized, double-blind, crossover comparison of amlodipine and valsartan in African- Americans with hypertension using 24-hour ambulatory blood pressure monitoring
  26, p. 889-895 2006
• International Journal of Cardiology
  Hilleman, D. E. Cost considerations with tight glycemic control in the acute care setting
  18, p. 359-365 2006
• Pharmacotherapy
  Burns, T. L., Mooss, A. N., Hilleman, D. E. Antiplatelet drug resistance: Not ready for prime time
  25, p. 1621-1628 2005
• American Journal of Cardiovascular Drugs
  Hilleman, D. E., Hunter, C. B., Mohiuddin, S. M., Maciejewski, S. Creighton University Cardiac Center, Omaha, NE, USA; Pharmacological management of atrial fibrillation following cardiac surgery
  5, p. 361-369 2005
• Journal of Managed Care Pharmacy
  Hilleman, D. E. New treatment options in COPD
  11, p. S12-S19 2005
• Ethnicity and Disease
  Packard, K. A., Majeed, F., Mohiuddin, S. M., Mooss, A. N., Hilleman, D. E., Arouni, A. J. Low high-density lipoprotein cholesterol is associated with impaired endothelial function in Asian Indians
  15, p. 555-561 2005
• Pharmacotherapy
  Lenz, T. L., Foral, P. A., Malesker, M. A., Hunter, C. B., Hilleman, D. E. Impact of nesiritide on health care resource utilization and complications in patients with decompensated heart failure
  24, p. 1137-1146 2004
• Pharmacotherapy
  Hilleman, D. E., Faulkner, M. A., Monaghan, M. S. Cost of a pharmacist-directed intervention to increase treatment of hypercholesterolemia
  24, p. 1077-1083 2004
• Pharmacotherapy
  Hilleman, D. E., Lucas, B. D. Angiotensin-converting enzyme inhibitors and stroke risk: Benefit beyond blood pressure reduction?
  24, p. 1064-1076 2004
• Journal of Vascular Surgery
  Sarac, T. P., Hilleman, D., Arko, F. R., Zarins, C. K., Ouriel, K. Clinical and economic evaluation of the trellis thrombectomy device for arterial occlusions: Preliminary analysis
  39, p. 556-559 2004
• Chest
  Foral, P. A., Malesker, M. A., Huerta, G., Hilleman, D. E. Nebulized opioids use in COPD
  125, p. 691-694 2004
• Pharmacotherapy
  Faulkner, M. A., Hilleman, D. E. Pharmacologic treatment of chronic obstructive pulmonary disease: Past, present, and future
  23, p. 1300-1315 2003
• Formulary
  Hilleman, D. E. Reducing cardiovascular risk in patients with type 2 diabetes: Management of dyslipidemia
  38, p. 478-497 2003
• Pharmacotherapy
  Hilleman, D. E., Spinler, S. A. Conversion of recent-onset atrial fibrillation with intravenous amiodarone: A meta-analysis of randomized controlled trials
  22, p. 66-74 2002
• Blood pressure monitoring
  Hilleman, D. E. Pharmacoeconomics of combination antihypertensive therapy
  6, p. S31-S36 2001
• Chest
  Nair, C. K., Khan, I. A., Esterbrooks, D. J., Ryschon, K. L., Hilleman, D. E. Diagnostic and prognostic value of holter-detected ST-segment deviation in unselected patients with chest pain referred for coronary angiography - A long-term follow-up analysis
  120, p. 834-839 2001
• Pharmacotherapy
  Faulkner, M. A., Hilleman, D. E., Destache, C. J., Mooss, A. N. Potential influence of timing of low-density lipoprotein cholesterol evaluation in patients with acute coronary syndrome
  21, p. 1055-1060 2001
• Journal of human hypertension
  Hilleman, D. E., Reyes, A. P., Wurdeman, R. L., Faulkner, M. Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension
  15, p. 559-565 2001
• Pharmacotherapy
  Lenz, T. L., Wurdeman, R. L., Hilleman, D. E. Comparison of 24-hour blood pressure profiles in patients with hypertension who were switched from amlodipine to nisoldipine
  21, p. 898-903 2001
• Annals of Pharmacotherapy
  Spinler, S. A., Hilleman, D. E., Cheng, J. W.M., Howard, P. A., Mauro, V. F., Lopez, L. M., Munger, M. A., Gardner, S. F., Nappi, J. M. New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines
  35, p. 589-617 2001
• Pharmacotherapy
  Hilleman, D. E., Bauman, J. L. Role of antiarrhythmic therapy in patients at risk for sudden cardiac death: An evidence-based review
  21, p. 556-575 2001
• Pharmacotherapy
  Hilleman, D. E., Wurdeman, R. L., Lenz, T. L. Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease
  21, p. 410-415 2001
• Pharmacoeconomics
  Friedman, M., Hilleman, D. E. Economic burden of chronic obstructive pulmonary disease - Impact of new treatment options
  19, p. 245-254 2001
• Chest
  Hilleman, D. E., Dewan, N., Malesker, M., Friedman, M. Pharmacoeconomic evaluation of COPD
  118, p. 1278-1285 2000
• Annals of Pharmacotherapy
  Lenz, T. L., Hilleman, D. E. Aggrenox: A fixed-dose combination of aspirin and dipyridamole
  34, p. 1283-1290 2000
• Drugs of Today
  Lenz, T. L., Hilleman, D. E. Dofetilide: A new antiarrhythmic agent approved for conversion and/or maintenance of atrial fibrillation/atrial flutter
  36, p. 759-771 2000
• American Journal of Health-System Pharmacy
  Hilleman, D. E. Role of angiotensin-converting-enzyme inhibitors in the treatment of hypertension
  57, p. S8-S11 2000
• Formulary
  Hilleman, D. E. New approaches to the management of AMI: Fibrinolysis plus GP IIb/IIIa receptor blockade
  35, p. 738-751 2000
• Pharmacotherapy
  Hilleman, D. E., Heineman, S. M., Foral, P. A. Pharmacoeconomic assessment of HMG-CoA reductase inhibitor therapy: An analysis based on the CURVES study
  20, p. 819-822 2000
• American Heart Journal
  Mooss, A. N., Wurdeman, R. L., Mohiuddin, S. M., Reyes, A. P., Sugimoto, J. T., Scott, W., Hilleman, D. E., Seyedroudbari, A. Esmolol versus diltiazem in the treatment of postoperative atrial fibrillation/atrial flutter after open heart surgery
  140, p. 176-180 2000
• Pharmacotherapy
  Skrabal, M. Z., Stading, J. A., Behmer-Miller, K. A., Hilleman, D. E. Advances in the treatment of congestive heart failure: New approaches for an old disease
  20, p. 787-804 2000
• Pharmacotherapy
  Lenz, T. L., Hilleman, D. E. Dofetilide, a new class III antiarrhythmic agent
  20, p. 776-786 2000
• Journal of Thrombosis and Thrombolysis
  Seyedroudbari, A., Kessler, E. R., Mooss, A. N., Wurdeman, R. L., Bala, M., Hilleman, D. E. Time to treatment and cost of thrombolysis: A multicenter comparison of tPA and rPA
  9, p. 303-308 2000
• Pharmacotherapy
  Faulkner, M. A., Wadibia, E. C., Lucas, B. D., Hilleman, D. E. Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: A randomized, controlled trial
  20, p. 410-416 2000
• convenient care
  Hilleman DE, Mohiuddin SM. Collaborative obesity management: advanced practice clinicians working with patients. Convenient Care 2015; 9: 20-21.
• Clinical Lipidology
  Mason RP, Hilleman DE. Omega-3 fatty acid fish oil dietary supplements for disease management: are they appropriate for patients? Lipid Spin 2016; 14: 29-31.

Publications

• Pharmacotherapy
  Malesker MA, Dehal N, Hilleman DE. Opioid-sparing effect of liposomal bupivacaine in total knee arthroplasty patients: a systematic analysis of randomized controlled trials. Pharmacotherapy 2020; 3:1225 (Abstract). 2020
• Journal of Managed Care & Specialty Pharmacy
  Hilleman DE, Malesker MA. Utilization of dabigatran in patients with atrial fibrillation: impact of the ACCP guidelines and the SAMe-TT2R2 score. J Man Care Pharm 2015; 21: S47.
  21, p. S47 2015
• Deshmukh A, Patel N, Azzouz M, Haroon S, Hilleman DK, Kaushik M, White M, DelCore M, Mooss A, Esterbrooks D, Lanspa T. Efficacy and safety of transradial approach to renal artery interventions. J Am Coll Cardiol Intv 2014; 7(2S): S38.
  7(2S), p. S38 2014
• Deshmukh A, Patel N, Kandasamy V, Hilleman DE, et al. Radial versus femoral approach to high speed rotational atherectomy. J Am Coll Cardiol Intv 2014; 7: S29-S30.
  7, p. s29-s30 2014
• Chest
  Au T, Malesker M, Hilleman DE, et al. A retrospective analysis of dexmedetomidine use for alcohol withdrawal syndrome in critical care patients. Chest 2014; 146: 225A.
  146, p. 225A 2014
• Critical Care Medicine
  Malesker MA, Hawkins E, Hilleman DE, Morrow LE. Intermittent bolus dosing vs continuous infusion furosemide in ICU patients with diuretic resistance. Crit Care Med 2013; 41:3 (abstract).
  41, p. 3 2013
• Hilleman D, Ling H, Luoma J. A review and comparison of fenofibrate and fenofibric acid formulations available in the United States. American Academy of Nurse Practitioners; June 2012; Orlando, FL. Abstract 24. 2012
• Chest
  Hawkins E, Malesker M, Hilleman D, Morrow L. A retrospective analysis of intermittent bolus dosing versus continuous infusion dosing of furosemide in critical care patients with diuretic resistance. Chest 2012; 142: 402A.
  142, p. 402A 2012
• Pharmacotherapy
  Hawkins E, Ling H, Burns T, Hilleman D. Perceptions, knowledge, and patterns of use of “fish oil” products in cardiac patients. Pharmacotherapy, 2012; 32: e184.
  32, p. e184 2012
• Pharmacotherapy
  Hawkins E, Ling H, Burns T, Mooss A, Hilleman D. Aliskiren in patients failing to achieve blood pressure targets with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Pharmacotherapy 2012; 32: e184.
  32, p. e184 2012
• Chest
  Hawkins E, Malesker M, Hilleman D, Morrow L. A retrospective analysis of intermittent bolus dosing versus continuous infusion dosing of furosemide in critical care patients with diuretic resistance. Chest 2012; 142: 402A.
  142, p. 402A 2012
• Kaushik M, Deshmukh A, Pandva J, Hilleman D, Esterbrooks D, Mohiuddin S. Echocardiographic correlates of persistent ST-elevation on ECG in STEMI patients undergoing percutaneous coronary intervention. JACC 2012; 60 (suppl B): B148.
  60, p. B148 2012
• Chest
  Malesker, MA, Boldt D, Ling H, Burns T, Hilleman DE. Impact of the ACCP antithrombotic guidelines on potential utilization of dabigatran in patients with atrial fibrillation. Chest 2013; 144: 161A.
  144, p. 161A 2012

General

• Cardiovascular Therapeutics
  Packard KA, Hilleman DE. Adherence to therapies for secondary prevention of cardiovascular disease: focus on aspirin. Cardiovascular Ther 2016; 34: 415-422. 2016